United States

U.S. secures GSK-Vir COVID-19 antibody therapy doses worth $1 bln

3 minute read
1/2

A general view outside the Glaxo Smith Kline pharmaceutical company headquarters in West London following the outbreak of the coronavirus disease (COVID-19), London, Britain, May 5, 2020. REUTERS/Toby Melville

Register now for FREE unlimited access to Reuters.com
  • Globally more than 750,000 doses of treatment secured
  • U.S. supply expected by mid-December
  • U.S. gave the drug emergency use approval in May

Nov 17 (Reuters) - The United States has signed contracts worth about $1 billion for doses of the antibody-based COVID-19 treatment from Britain's GSK (GSK.L) and U.S.-based Vir Biotechnology (VIR.O), as countries seek to secure promising options beyond vaccines.

The drugmakers said on Wednesday the U.S. orders bring the total number of doses to be supplied to more than 750,000 globally, without specifying how many doses of the treatment, sotrovimab, the U.S. government had signed up for.

However, other public deals for the drug include 10,000 doses for Canada and up to 220,000 doses for the European Union. Values of those orders have not been disclosed.

Register now for FREE unlimited access to Reuters.com

U.S. deliveries of the treatment, branded Xevudy, are expected by Dec. 17 and the government will also have an option to buy more doses through March 2022, GSK and Vir said in their joint statement.

While vaccines remain at the heart of the long-term fight against the COVID-19 pandemic, treatments including game-changing antiviral pills from Merck (MRK.N) and Pfizer (PFE.N), offer options to contain infections and save lives.

Pfizer said on Tuesday it was seeking U.S. authorisation of its experimental antiviral COVID-19 pill that cut the chance of hospitalization or death for adults at risk of severe disease by 89% in a clinical trial. read more

GSK-Vir's sotrovimab has shown to reduce that risk by 79% in trials.

Unlike oral options from Merck and Pfizer, sotrovimab is given via an infusion. It belongs to a class of medicines called monoclonal antibodies which are lab-generated compounds that mimic the body's natural defences.

The therapy was authorised for emergency use in the United States in May to prevent mild or moderate cases of COVID-19 from worsening. The European regulator has given its go-ahead for use by member states, although EU-wide approval is still pending.

"Given ongoing evidence, which demonstrates its ability to maintain activity against the tested circulating variants of concern, including Delta, we are confident sotrovimab will continue to be important," Vir Chief Executive George Scangos said.

Last week, GSK and Vir said the antibody treatment was shown in a trial to work as well when given as a shot in the arm when administered via the standard infusion, potentially offering more convenience. read more

Sotrovimab brought in sales of 130 million pounds ($175 million) for GSK in the first nine months of 2021.

Similar products are offered or being developed by Eli Lilly (LLY.N), Regeneron (REGN.O), AstraZeneca (AZN.L) and Celltrion (091990.KQ).

Last month U.S. authorities said the government would control distribution of sotrovimab in the country.

($1 = 0.7427 pounds)

Register now for FREE unlimited access to Reuters.com
Reporting by Pushkala Aripaka in Bengaluru; Editing by Sherry Jacob-Phillips, Edmund Blair and Angus MacSwan

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters